ArticleFrontiers in immunology2026

Case Report: Targeted interleukin-6 blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers.

Jean-François Rossi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.